SANTA CLARA, Calif., Feb. 24, 2011 /PRNewswire/ — PR Newswire
– NewCardio, Inc., (OTC Bulletin Board:
NWCI) a cardiovascular diagnostic solutions developer,
announced today that the Company has been invited by the Heart
Rhythm Society (HRS) to present results of a recent clinical study
showing that recurrent atrial fibrillation (AF) was accurately and
timely detected in patients who used CardioBip™ for daily
monitoring following catheter ablation procedures. The
presentation, entitled “Long-term Intermittent Wireless Remote
Monitoring of Reconstructed 12-Lead ECG in Post-Ablation AF
Patients Using the CardioBip System”, will be made at the 32nd
Annual Scientific Sessions of the HRS, to be held in San Francisco,
CA, May 4-7, 2011.
AF affects an estimated 1% of the worldwide population, with
nearly three million AF patients in the US and six million AF
patients in Europe. It is a serious medical condition that
doubles mortality risk and increases risk of stroke by five-fold.
Accordingly, such patients often need ambulatory monitoring to
detect AF recurrences. Currently available AF monitoring devices
have significant limitations, such as relatively few monitoring
leads and the need to wear a device with attached wires and skin
electrodes. CardioBip addresses these limitations as it does not
employ any skin electrodes or wires. The handheld device
conveniently records and wirelessly transmits information
sufficient to reconstruct a full 12-lead ECG.
Vincent Renz, CEO of NewCardio, commented, “We are delighted to
be presenting our latest CardioBip clinical study at the HRS Annual
Scientific Meeting, a prestigious forum that is well-attended by
cardiologists and electrophysiologists with a particular interest
in novel solutions for long-term ambulatory cardiac monitoring. The
exciting data from this study provide additional and very solid
supporting evide
‘/>”/>
